Latest 8-K filings

SoundThinking, Inc. has entered into a definitive merger agreement with Transom Capital Group, under which Transom will acquire the company for $8.00 per share in cash plus a contingent value right (CVR) of up to $3.00 per share.

Cartesian Therapeutics announced additional positive retreatment data for Descartes-08 in myasthenia gravis patients, showing deep and durable responses.

Invivyd announces positive topline results from its LIBERTY Phase 3 study for VYD2311, demonstrating superior safety and tolerability compared to an mRNA COVID-19 vaccine and paving the way for regulatory submission.

Aquestive Therapeutics announced the appointment of Richard J. Daly to its Board of Directors, effective October 14, 2026, strengthening its leadership with extensive life sciences executive experience.

JELD-WEN Holding, Inc. announced a comprehensive agreement to extend debt maturities and raise $135 million in new liquidity, aiming to strengthen its capital structure and support its business plan.

Iovance Biotherapeutics has increased its full-year 2026 revenue forecast to $410-$420 million, citing strong demand for Amtagvi and Proleukin.

The Sherwin-Williams Company has entered into a new $750 million senior unsecured term loan credit agreement, replacing its existing facility and providing flexibility for general corporate purposes.

1-800-Flowers.com, Inc. announced it has entered into a definitive agreement to sell its PersonalizationMall.com and Things Remembered businesses to PlanetArt, LLC for approximately $45 million in cash.

Altimmune, Inc. announced the appointment of Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026.

BeyondSpring Inc. announced a strategic transaction to sell its majority equity interest in its Chinese subsidiary to Biolin Investment Limited, securing funding for the global Phase 3 DUBLIN-4 trial.

Aldeyra Therapeutics will submit a Formal Dispute Resolution Request to the FDA appealing the denial of its New Drug Application for reproxalap for dry eye disease, extending its cash runway into 2029.

CID HoldCo, Inc. has entered into a Securities Purchase Agreement to acquire 100% of Envoy Technologies, Inc. from BladeRanger Ltd., with the transaction valued at $65 million.

CarMax announced robust second quarter fiscal year 2027 results, with total net revenues up 19.5% and diluted EPS soaring 81.3%, alongside plans to resume share repurchases.

Immix Biopharma announced an 89% complete response rate in its Phase 2 NEXICART-2 trial for NXC-201 in relapsed/refractory AL Amyloidosis patients.

Atlantic Union Bankshares Corporation announced its third quarter 2026 financial results conference call and webcast scheduled for October 20, 2026.

T1 Energy Inc. announced the sale of $50 million in 4.75% Convertible Senior Notes due 2031 to a qualified institutional buyer to fund infrastructure development for its solar cell fab.

Alzamend Neuro's novel lithium compound, AL001, shows a trend towards improved brain delivery and pharmacokinetics compared to traditional lithium salts in a Phase 1/2A clinical trial.

Westlake Corporation announced plans to close its PVC production plant in Cologne, Germany, by Q1 2027, expecting to incur approximately $205 million in pre-tax charges.

Liberty Star Uranium & Metals Corp. has entered into a Securities Purchase Agreement to issue a convertible promissory note to Monroe Street Capital Partners LP, securing $95,700 in principal financing.

Stewards, Inc. has entered into a Registration Rights Agreement with sellers of acquired membership interests, ensuring liquidity for 'Registrable Securities' through resale registration.

Uranium Energy Corp announces a transformational fiscal year 2026, establishing itself as a multi-mine U.S. uranium producer with significant production increases and cost reductions.

Summit Therapeutics announces a $2 billion strategic equity investment from AstraZeneca and a clinical trial collaboration to evaluate ivonescimab.

VerifyMe, Inc. has filed a Form 8-K providing pro forma financial information for its proposed merger with Open World Ltd., detailing combined financial statements and the accounting treatment of the transaction.

Korn Ferry's stockholders approved an amended stock incentive plan and ratified director elections at the 2026 Annual Meeting.

AAR Corp. announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings for $4.0 billion, significantly expanding its aviation aftermarket platform and enhancing its financial profile.

Glucotrack, Inc. has amended its common stock purchase warrants to comply with Nasdaq listing requirements, adjusting floor prices and anti-dilution provisions.

Polar Power, Inc. announced its CEO, Arthur Sams, has converted $614,700 of debt into Series A Convertible Preferred Stock, strengthening the company's balance sheet and addressing shareholder equity compliance.

Newbury Street II Acquisition Corp has announced an extraordinary general meeting in lieu of an annual general meeting, setting deadlines for shareholder proposals.

Clearway Energy, Inc. subsidiary acquires Swan Solar project, a 650 MW solar facility, for approximately $230 million, with closing expected in Q3 2028.

Surf Air Mobility Inc. announced the appointment of Jason Secore as Chief Financial Officer, effective September 30, 2026, succeeding Oliver Reeves who will transition to an advisory role.